Ocular myasthenia gravis after D-penicillamine administration.
A 68-year-old black woman who was put on D-penicillamine therapy (250-500 mg per day, total dose 15 g) for rheumatoid arthritis developed ocular myasthenia gravis. Two weeks after she discontinued D-penicillamine her signs and symptoms cleared with no other treatment. Review of previous cases and possible immunological mechanisms are discussed.
Katz
L J
LJ
William and Anna Goldberg Glaucoma Service, Thomas Jefferson University, Philadelphia, PA 19107.
Lesser
R L
RL
Merikangas
J R
JR
Silverman
J P
JP
D000368:Aged; D001763:Blepharoptosis / Q000139:chemically induced*; D004172:Diplopia / Q000139:chemically induced*; D005260:Female; D006801:Humans; D009157:Myasthenia Gravis / Q000139:chemically induced*; D010396:Penicillamine / Q000009:adverse effects*
D010396:Penicillamine